International AMR Action! 21 Sep Wellcome Trust-UNGA event / 12-13 Oct Call to Action (Berlin)

Dear All: 

The international conversation continues apace following the recent DRIVE-AB meeting on antibiotic incentives. There are two further important meetings coming up that you may wish to know about.

First, Wellcome Trust is co-hosting a side-event with the UN Foundation during the UN General Assembly on 21 Sep (yes, this week!). The side event is from 8a-10a in New York City. Here is the registration link should you be in NYC on Thursday and able to attend. Panel discussions will focus on the challenges of developing multi-sectoral national action plans as well as covering progress on support mechanisms for antibiotic discovery. The keynote speakers look wonderful, including opening comments from the WHO’s DG:

  • Session title: One Year On: Progress, Challenges, Opportunities, and New Ways of Working to Tackle Antimicrobial Resistance (AMR)
  • Keynote: Dr. Tedros Adhanom Ghebreyesus; Director-General, World Health Organization; Co-Chair, UN Interagency Coordination Group on AMR
  • Keynote: Professor Dame Sally Davies; Chief Medical Officer, United Kingdom; Co-Convener, UN Interagency Coordination Group
  • Keynote: Ms. Maria Helena Semedo; Deputy Director-General, Food and Agriculture Organization of the United Nations
  • Closing: Honorable Dr. Aaron Motsoaledi; Minister of Health, South Africa

Second, Wellcome Trust is also organizing an AMR Call to Action Conference 12-13 October in Berlin. The event is “… an opportunity for national governments and multilateral institutions to come together with the civil society, private and philanthropic sectors to focus on the most critical gaps in tackling the development and spread of drug-resistant infections, and to commit to concerted and tangible actions.” If you think you might be interested in attending (it is invitation-only but I am told there is still some scope to add attendees), please contact Wellcome Trust by email at amrcalltoaction@wellcome.ac.uk.

It is fabulous to see these conversations at the political level … I know that we don’t yet have all the tools we need to ensure a vibrant antibiotic pipeline, but these conversations are the necessary prelude!

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Chief Strategy Officer, CARB-X | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog/

Upcoming meetings of interest to the AMR community:

Share

Impact of PASTEUR: 9.9m lives saved, ROI of 125:1

Impact of PASTEUR: 9.9m lives saved, ROI of 125:1 Dear All (and with thanks to Kevin Outterson for being lead author on this newsletter), (wonkish alert on this one … refresh your coffee and dig in!) The Center for Global Development have released a blog post and a paper estimating the potential impact of the PASTEUR Act.

Five FDA RFPs! Antifungal animal models, MIC breakpoints, and more!

Dear All, I just today learned that FDA have posted their FY 2023 funding opportunities. All the details are on this webpage and I’m just going to reproduce the text below my signature for your reference. I’ll also add a few details in italics. Lots of good opportunities here! –jr John H. Rex, MD |

WAAW! Must-Read Article, A Quiz, A Video, A Call to Action

Notes: Newsflash … BARDA have opened their long-running BAA-18-100-SOL-00003 to include support for antifungal agents. Search for “antifungal” in the posted .pdf to find the text. The first deadline for proposals is 15 Dec 2022 and further deadlines will doubtless follow: as shown on page 9, this BAA has offered 4 deadlines/year since 2018!  Dear All, In

Fireside Chat with AMR Action Fund CIO Martin Heidecker

Dear All, Ahead of World Antimicrobial Awareness Week, I sat down with AMR Action Fund Chief Investment Officer Martin Heidecker for a Fireside Chat. It was a fabulous conversation that covered everything from how the Fund’s investment process works to what it’s looking for in portfolio companies to broader investment trends in the AMR space.  As

Scroll to Top